Patients must not have experienced a grade or worse immune-related adverse event (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved irAE grade , nor have experienced a toxicity that led to permanent discontinuation of prior anti-PD-/PD-L immunotherapy
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Patient has had a prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior >= grade immune-related adverse event (irAE) while receiving immunotherapy, or any unresolved irAE > grade
Any history of a prior >= grade immune-related adverse event (irAE) while receiving any previous immunotherapy agent
Patient has had a prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Have had any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, have any unresolved irAE Grade >, or any irAE that led to the permanent discontinuation of prior immunotherapy.
Any prior grade ? immune-related adverse event (irAE) while receiving a prior immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Participants with any prior >= grade immune-related adverse event (irAE) which began while receiving immunotherapy
Participants with any unresolved immune-related adverse event (irAE) at time of study entry\r\n* Note: Subjects with =< grade thyroiditis and/or hypophysitis are an exception to this criterion and may qualify for the study
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior immune-related adverse event (irAE) >= grade while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Patient has had a prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade .
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy; any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved immune related adverse events (irAE) > grade
Must not have had a grade >= immune related adverse event (irAE) on nivolumab monotherapy (excluding endocrine toxicity managed with replacement therapy)
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nAny prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade as per National Cancer Institute (NCI)-CTCAE v.; patients with greater than + proteinuria at entry are ineligible
PHASE II STUDY COHORT OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nAny prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade as per NCI-CTCAE v.; patients with greater than + proteinuria at entry are ineligible
PHASE II STUDY COHORT TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade as per NCI-CTCAEv.
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
PHASE II COLORECTAL CANCER COHORT (MEDI+C ONLY):\r\nAny prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade ; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade as per NCI-CTCAEv.; patients with greater than + proteinuria at entry are ineligible
Any prior grade >= immune-related adverse event (irAE) while receiving immunotherapy (including anti-cytotoxic T-lymphocyte antigen [CTLA-] or anti-cluster of differentiation [CD] monoclonal antibody [MAb]) or any unresolved irAE of any grade (controlled irAE endocrinopathies are allowed)
Must not have experienced an immune-related adverse event (irAE) where the irAE was the reason for permanent discontinuation of prior immunotherapy in the most recent prior treatment regimen
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Has any prior Grade ? immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- treatment, or any unresolved irAE >Grade .
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade except for endocrine adverse events (AEs) managed with replacement therapy; any other AEs unresolved toxicities grade or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalities
DOSE ESCALATION COHORT: Any prior ? grade immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- and anti-PD-/PD-L treatment, or any unresolved irAE > grade \r\n* Note: Previous immune-related ocular toxicity of any grade is excluded
DOSE EXPANSION COHORT: Any prior ? grade immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA- and anti-PD-/PD-L treatment, or any unresolved irAE > grade ; Note: previous immune-related ocular toxicity of any grade is excluded
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Patients must not have any prior grade >= immune-related adverse event (irAE) or any unresolved irAE > grade
Patients must not have any prior grade >= immune-related adverse event (irAE) or any unresolved irAE > grade (MEDI RE-TREATMENT)
Any prior Grade ? immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade
Any prior Grade ? immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade
Any prior Grade ? immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE.
Any prior Grade ? irAE while receiving immunotherapy
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any prior grade >= immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade
Any clinically significant Grade ? immune-related adverse event (irAE)
Any grade neurologic or ocular irAE
For Arms L (pembrolizumab) and M (nivolumab), history of a prior grade or immune-related adverse event (irAE) or any grade ocular irAE from prior immunotherapy
